share_log

Pacira BioSciences Analyst Ratings

Pacira BioSciences Analyst Ratings

Pacira 生物科学分析师评级
Benzinga ·  2023/10/03 10:56
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/03/2023 132.08% RBC Capital → $68 Reiterates Outperform → Outperform
08/03/2023 70.65% Piper Sandler $60 → $50 Maintains Overweight
08/03/2023 87.71% Truist Securities $60 → $55 Maintains Buy
08/03/2023 132.08% RBC Capital $70 → $68 Maintains Outperform
08/03/2023 70.65% TD Cowen → $50 Upgrades Market Perform → Outperform
08/03/2023 115.02% HC Wainwright & Co. $68 → $63 Maintains Buy
08/03/2023 77.47% Needham $60 → $52 Maintains Buy
07/13/2023 132.08% HC Wainwright & Co. $71 → $68 Maintains Buy
05/15/2023 104.78% Piper Sandler → $60 Maintains Overweight
05/04/2023 145.73% RBC Capital $75 → $72 Maintains Outperform
05/04/2023 142.32% HC Wainwright & Co. → $71 Reiterates → Buy
04/25/2023 111.6% Piper Sandler → $62 Maintains Overweight
04/20/2023 104.78% Needham → $60 Reiterates → Buy
03/01/2023 159.39% RBC Capital $80 → $76 Maintains Outperform
03/01/2023 142.32% HC Wainwright & Co. $69 → $71 Maintains Buy
02/28/2023 104.78% Needham $63 → $60 Maintains Buy
02/10/2023 135.49% HC Wainwright & Co. $76 → $69 Reiterates → Buy
01/31/2023 104.78% Wedbush → $60 Assumes → Outperform
01/06/2023 77.47% BMO Capital $60 → $52 Maintains Market Perform
01/06/2023 115.02% Needham $66 → $63 Maintains Buy
11/07/2022 104.78% BMO Capital $66 → $60 Maintains Market Perform
11/04/2022 159.39% HC Wainwright & Co. $83 → $76 Maintains Buy
11/03/2022 152.56% Needham $76 → $74 Maintains Buy
10/21/2022 125.26% Jefferies → $66 Assumes → Buy
08/04/2022 159.39% Piper Sandler $80 → $76 Maintains Overweight
07/21/2022 173.04% Piper Sandler $84 → $80 Maintains Overweight
06/15/2022 159.39% Needham $84 → $76 Maintains Buy
02/28/2022 220.82% Wedbush $97 → $94 Maintains Outperform
02/25/2022 207.17% HC Wainwright & Co. $86 → $90 Maintains Buy
01/19/2022 227.65% Barclays $92 → $96 Maintains Overweight
11/05/2021 213.99% Barclays $91 → $92 Maintains Overweight
11/04/2021 193.52% HC Wainwright & Co. $80 → $86 Maintains Buy
10/18/2021 186.69% Needham $80 → $84 Maintains Buy
10/12/2021 173.04% HC Wainwright & Co. $84 → $80 Maintains Buy
10/01/2021 210.58% Barclays $95 → $91 Maintains Overweight
08/04/2021 186.69% HC Wainwright & Co. $86 → $84 Maintains Buy
07/26/2021 155.97% JP Morgan → $75 Upgrades Neutral → Overweight
05/10/2021 138.91% BMO Capital $72 → $70 Maintains Market Perform
05/05/2021 125.26% Northland Capital Markets $75 → $66 Maintains Market Perform
04/09/2021 217.41% Berenberg → $93 Initiates Coverage On → Buy
03/01/2021 193.52% HC Wainwright & Co. $70 → $86 Maintains Buy
01/21/2021 155.97% SVB Leerink $63 → $75 Downgrades Outperform → Market Perform
01/08/2021 159.39% Needham $67 → $76 Maintains Buy
12/09/2020 128.67% Needham $68 → $67 Maintains Buy
11/02/2020 183.28% Wedbush $85 → $83 Maintains Outperform
09/21/2020 128.67% Northland Capital Markets $58 → $67 Upgrades Market Perform → Outperform
09/09/2020 132.08% Needham $64 → $68 Maintains Buy
07/13/2020 132.08% HC Wainwright & Co. $63 → $68 Reiterates → Buy
07/10/2020 135.49% Jefferies $53 → $69 Maintains Buy
07/06/2020 118.43% Needham $52 → $64 Maintains Buy
05/27/2020 — Guggenheim Initiates Coverage On → Neutral
05/08/2020 63.82% Stifel $49 → $48 Maintains Hold
05/08/2020 53.58% SVB Leerink $44 → $45 Maintains Outperform
04/30/2020 77.47% Needham $56 → $52 Maintains Buy
04/07/2020 70.65% Northland Capital Markets → $50 Initiates Coverage On → Outperform
03/20/2020 50.17% SVB Leerink $46 → $44 Upgrades Market Perform → Outperform
02/24/2020 115.02% HC Wainwright & Co. $60 → $63 Maintains Buy
01/24/2020 104.78% SunTrust Robinson Humphrey → $60 Initiates Coverage On → Buy
11/06/2019 91.13% BTIG → $56 Initiates Coverage On → Buy
08/09/2019 46.76% BMO Capital $46 → $43 Maintains Market Perform
06/11/2019 77.47% Barclays → $52 Initiates Coverage On → Overweight
05/06/2019 29.69% Mizuho $29 → $38 Upgrades Underperform → Neutral
02/01/2019 — Mizuho Downgrades Neutral → Underperform
11/02/2018 70.65% JP Morgan $45 → $50 Maintains Neutral
11/02/2018 60.41% BMO Capital $40 → $47 Maintains Market Perform
11/02/2018 115.02% JMP Securities $56 → $63 Maintains Market Outperform
10/10/2018 63.82% B of A Securities $46 → $48 Maintains Neutral
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
10/03/2023 132.08% 加拿大皇家银行资本 →$68 重申 跑赢→跑赢大盘
08/03/2023 70.65% 派珀·桑德勒 $60→$50 维护 超重
08/03/2023 87.71% Truist证券 $60→$55 维护 买
08/03/2023 132.08% 加拿大皇家银行资本 $70→$68 维护 跑赢大盘
08/03/2023 70.65% TD Cowen →$50 升级 市场表现优于→
08/03/2023 115.02% HC Wainwright公司 $68→$63 维护 买
08/03/2023 77.47% 李约瑟 $60→$52 维护 买
07/13/2023 132.08% HC Wainwright公司 $71→$68 维护 买
2023年05月15日 104.78% 派珀·桑德勒 →$60 维护 超重
05/04/2023 145.73% 加拿大皇家银行资本 $75→$72 维护 跑赢大盘
05/04/2023 142.32% HC Wainwright公司 →$71 重申 →购买
04/25/2023 111.6% 派珀·桑德勒 →$62 维护 超重
04/20/2023 104.78% 李约瑟 →$60 重申 →购买
03/01/2023 159.39% 加拿大皇家银行资本 $80→$76 维护 跑赢大盘
03/01/2023 142.32% HC Wainwright公司 $69→$71 维护 买
02/28/2023 104.78% 李约瑟 $63→$60 维护 买
02/10/2023 135.49% HC Wainwright公司 $76→$69 重申 →购买
2023年1月31日 104.78% 韦德布什 →$60 假设 →跑赢大盘
01/06/2023 77.47% 蒙特利尔银行资本 $60→$52 维护 市场表现
01/06/2023 115.02% 李约瑟 $66→$63 维护 买
11/07/2022 104.78% 蒙特利尔银行资本 $66→$60 维护 市场表现
11/04/2022 159.39% HC Wainwright公司 $83→$76 维护 买
11/03/2022 152.56% 李约瑟 $76→$74 维护 买
2022年10月21日 125.26% 杰富瑞 →$66 假设 →购买
08/04/2022 159.39% 派珀·桑德勒 $80→$76 维护 超重
07/21/2022 173.04% 派珀·桑德勒 $84→$80 维护 超重
2022/06/15 159.39% 李约瑟 $84→$76 维护 买
02/28/2022 220.82% 韦德布什 $97→$94 维护 跑赢大盘
02/25/2022 207.17% HC Wainwright公司 $86→$90 维护 买
2022年1月19日 227.65% 巴克莱 $92→$96 维护 超重
2021年11月05日 213.99% 巴克莱 $91→$92 维护 超重
11/04/2021 193.52% HC Wainwright公司 $80→$86 维护 买
10/18/2021 186.69% 李约瑟 $80→$84 维护 买
10/12/2021 173.04% HC Wainwright公司 $84→$80 维护 买
10/01/2021 210.58% 巴克莱 $95→$91 维护 超重
08/04/2021 186.69% HC Wainwright公司 $86→$84 维护 买
07/26/2021 155.97% 摩根大通 →$75 升级 中性→超重
2021/05/10 138.91% 蒙特利尔银行资本 $72→$70 维护 市场表现
05/05/2021 125.26% 北国资本市场 $75→$66 维护 市场表现
04/09/2021 217.41% 贝伦伯格 →$93 开始承保 →购买
03/01/2021 193.52% HC Wainwright公司 $70→$86 维护 买
2021/01/21 155.97% SVB Leerink $63→$75 评级下调 跑赢→市场表现
01/08/2021 159.39% 李约瑟 $67→$76 维护 买
12/09/2020 128.67% 李约瑟 $68→$67 维护 买
11/02/2020 183.28% 韦德布什 $85→$83 维护 跑赢大盘
2020/09/21 128.67% 北国资本市场 $58→$67 升级 市场表现优于→
09/09/2020 132.08% 李约瑟 $64→$68 维护 买
07/13/2020 132.08% HC Wainwright公司 $63→$68 重申 →购买
07/10/2020 135.49% 杰富瑞 $53→$69 维护 买
07/06/2020 118.43% 李约瑟 $52→$64 维护 买
05/27/2020 - 古根海姆 开始承保 →中性
05/08/2020 63.82% Stifel $49→$48 维护 保持
05/08/2020 53.58% SVB Leerink $44→$45 维护 跑赢大盘
04/30/2020 77.47% 李约瑟 $56→$52 维护 买
04/07/2020 70.65% 北国资本市场 →$50 开始承保 →跑赢大盘
03/20/2020 50.17% SVB Leerink $46→$44 升级 市场表现优于→
02/24/2020 115.02% HC Wainwright公司 $60→$63 维护 买
1/24/2020 104.78% SunTrust Robinson Humphrey →$60 开始承保 →购买
2019/06/11 91.13% BTIG →$56 开始承保 →购买
2019年08月09日 46.76% 蒙特利尔银行资本 $46→$43 维护 市场表现
2019年6月11日 77.47% 巴克莱 →$52 开始承保 →超重
2019年05月06日 29.69% 瑞穗 $29→$38 升级 表现不佳的→中性
2019年02月01日 - 瑞穗 评级下调 中性→表现不佳
11/02/2018 70.65% 摩根大通 $45→$50 维护 中性
11/02/2018 60.41% 蒙特利尔银行资本 $40→$47 维护 市场表现
11/02/2018 115.02% JMP证券 $56→$63 维护 市场表现强于大盘
2018年10月10日 63.82% B of A证券 $46→$48 维护 中性

What is the target price for Pacira BioSciences (PCRX)?

Pacira BioSciences(PCRX)的目标价格是多少？

The latest price target for Pacira BioSciences (NASDAQ: PCRX) was reported by RBC Capital on October 3, 2023. The analyst firm set a price target for $68.00 expecting PCRX to rise to within 12 months (a possible 132.08% upside). 24 analyst firms have reported ratings in the last year.

加拿大皇家银行资本于2023年10月3日报道了Pacira BioSciences(纳斯达克：PCRX)的最新目标价。这家分析公司将目标价定为68美元，预计PCRX将在12个月内上涨(可能上涨132.08%)。去年有24家分析公司公布了评级。

What is the most recent analyst rating for Pacira BioSciences (PCRX)?

Pacira BioSciences(PCRX)的最新分析师评级是什么？

The latest analyst rating for Pacira BioSciences (NASDAQ: PCRX) was provided by RBC Capital, and Pacira BioSciences reiterated their outperform rating.

加拿大皇家银行资本对太平洋生物科学公司(纳斯达克：PCRX)的最新分析师评级是由加拿大皇家银行资本提供的，太平洋生物科学公司重申了其表现优于大盘的评级。

When is the next analyst rating going to be posted or updated for Pacira BioSciences (PCRX)?

Pacira BioSciences(PCRX)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Pacira BioSciences的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Pacira BioSciences的上一次评级是在2023年10月3日提交的，因此您应该预计下一次评级将在2024年10月3日左右提供。

Is the Analyst Rating Pacira BioSciences (PCRX) correct?

分析师对Pacira BioSciences(PCRX)的评级正确吗？

While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a reiterated with a price target of $0.00 to $68.00. The current price Pacira BioSciences (PCRX) is trading at is $29.30, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Pacira BioSciences(PCRX)评级被重申，目标价在0.00美元至68.00美元之间。Pacira BioSciences(PCRX)目前的交易价格为29.30美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发